Evidence map›Paper›PMID 38847906›Full record

ReviewCardiovascular drugs and therapy2025

Cardiorenal Syndrome in Right Heart Failure Due to Pulmonary Arterial Hypertension-The Right Ventricle as a Therapeutic Target to Improve Renal Function.

Kenzo Ichimura, Adam Gross, Roy O Mathew, Loay Salman, Sushma Reddy, Edda Spiekerkoetter, Mandeep S Sidhu

Abstract readReview
PubMed Publisher
In one paragraph

Review in Cardiovascular drugs and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Kenzo IchimuraDepartment of Medicine, Division of Pulmonary, Allergy and Critical Care, Stanford University, 1701 Page Mill Road, Palo Alto, CA, 94304, USA. kennzo@stanford.edu.ORCID 0000-0002-5734-335X
Adam GrossAlbany Medical College, Albany, NY, 12208, USA.
Roy O MathewDepartment of Medicine, Loma Linda VA Health Care System, Loma Linda, CA, 92357, USA.
Loay SalmanDivision of Nephrology, Department of Medicine, Albany Medical College, Albany, NY, 12208, USA.
Sushma ReddyCardiovascular Institute, Stanford University, Stanford, CA, 94305, USA.
Edda SpiekerkoetterDepartment of Medicine, Division of Pulmonary, Allergy and Critical Care, Stanford University, 1701 Page Mill Road, Palo Alto, CA, 94304, USA.
Mandeep S SidhuDivision of Cardiology, Department of Medicine, Department of Medical Education, Albany Medical College, Albany, NY, 12208, USA.

Funding

Targeting Novel BMPR2 modifiers in Pulmonary Hypertension with Repurposed DrugsR01HL128734 · NHLBI · STANFORD UNIVERSITY · PI SPIEKERKOETTER, EDDA FRAUKE · 2016 to 2020
$2.1M
Understanding and targeting molecular as well as structural events governing right ventricular adaptation, failure and recovery in pulmonary hypertension using repurposed drugsR01HL158868 · NHLBI · STANFORD UNIVERSITY · PI SPIEKERKOETTER, EDDA FRAUKE · 2021 to 2024
$1.7M
American Heart Association 903768NHLBI NIH HHS R01 HL128734NHLBI NIH HHS R01 HL158868-01Stanford Cardiovascular Institute, School of Medicine, Stanford University Stanford Cardiovascular Institute, School of Medicine, Stanford UniversityU.S. Department of Defense PR 117996U.S. Department of Defense PR161256U.S. Department of Defense PR181774
6 · The paper itself

Abstract

Cardiorenal syndrome (CRS) due to right ventricular (RV) failure is a disease entity emerging as a key indicator of morbidity and mortality. The multifactorial aspects of CRS and the left-right ventricular interdependence complicate the link between RV failure and renal function. RV failure has a direct pathophysiological link to renal dysfunction by leading to systemic venous congestion in certain circumstances and low cardiac output in other situations, both leading to impaired renal perfusion. Indeed, renal dysfunction is known to be an independent predictor of mortality in patients with pulmonary arterial hypertension (PAH) and RV failure. Thus, it is important to further understand the interaction between the RV and renal function. RV adaptation is critical to long-term survival in patients with PAH. The RV is also known for its remarkable capacity to recover once the aggravating factor is addressed or mitigated. However, less is known about the renal potential for recovery following the resolution of chronic RV failure. In this review, we provide an overview of the intricate relationship between RV dysfunction and the subsequent development of CRS, with a particular emphasis on PAH. Additionally, we summarize potential RV-targeted therapies and their potential beneficial impact on renal function.

Indexed as

Arterial PressureCardio-Renal SyndromeHeart FailureKidneyPulmonary Arterial HypertensionVentricular Dysfunction, RightVentricular Function, RightAnimalsHumansRecovery of FunctionCardiorenal syndromePulmonary arterial hypertensionRenocardiac syndromeRight heart failure

Identifiers

PMID38847906

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.